A prospective case control interventional study to assess safety and efficacy of proprietary Ayurvedic medicine Tab. â??CoReachâ?? in non-critical and antiviral naÃ¯ve COVID-19 positive patients

Questt Clinicals and Ayurceuricals Pvt Ltd0 个研究点目标入组 106 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•I. Patients with laboratory confirmation of infection with SARS CoV-2 by positive RT-PCR or Rapid Antigen Test with mild to moderate symptoms (Mild: Upper respiratory tract symptoms (& or fever) WITHOUT shortness of breath or hypoxia
•Moderate: Any one of: 1. Respiratory rate > 24/min, breathlessness 2. SpO2: 90% to < 93% on room air
•Ref: AIIMS ICMR-COVID-19 National Task Force)
•Patients progressing from moderate to severe grade during treatment will be withdrawn from the study
•II. Age >18 and < 75 years at the time of signing ICF
•III. Voluntarily participation in the clinical trial and agreeing to follow study procedures
•IV. Not participating in any other interventional drug clinical studies before completion of the present study
•V. Ready to give medical data for assessments

•I. Critical infection, defined as need for invasive ventilator support
•II. Inability to intake or tolerate oral medications.
•III. Known pregnant or lactating women
•IV. Persons with severe primary respiratory disease or other pneumonia
•V. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely.

发起方

Questt Clinicals and Ayurceuricals Pvt Ltd